SCHEMBL22407975

SCHEMBL22407975

COc1cc(F)cc2[nH]c(C)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39
AXL P30530 1/20 0.37
P2RX7 Q99572 1/20 0.37
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 3/20 0.37
HPGD P15428 3/20 0.37
MAPT P10636 1/20 0.37
ATM Q13315 1/20 0.37
IMPDH2 P12268 1/20 0.36
PDE3B Q13370 3/20 0.36
PDE3A Q14432 3/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
AHR P35869 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
RXFP1 Q9HBX9 1/20 0.35
KDR P35968 1/20 0.35
TUBB4A P04350 2/20 0.35
TUBB P07437 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29445889 1.00 KEAP1 (0.39) KEAP1NFE2L2AXLP2RX7ALDH1A1
SCHEMBL21983593 0.81 ACHE (0.45) AXLALDH1A1KDM4EHPGDMAPT
SCHEMBL22408270 0.78 LMNA (0.46) AXLALDH1A1KDM4EHPGDMAPT
SCHEMBL22408290 0.76 KEAP1 (0.43) KEAP1NFE2L2ALDH1A1KDM4EHPGD
SCHEMBL29445923 0.76 KEAP1 (0.43) KEAP1NFE2L2ALDH1A1KDM4EHPGD
SCHEMBL24038488 0.76 KEAP1 (0.43) KEAP1NFE2L2ALDH1A1KDM4EHPGD
SCHEMBL20504855 0.76 ADRB2 (0.35) ALDH1A1KDM4EHPGDSMN1; SMN2AHR
SCHEMBL29957902 0.76 ALDH1A1 (0.36) ALDH1A1KDM4EHPGDMAPTSMN1; SMN2
SCHEMBL3860178 0.74 KDM4E (0.45) P2RX7ALDH1A1KDM4EHPGDPDE3B
SCHEMBL2504301 0.74 ULK1 (0.53) KDM4EHPGDMAPTSMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3928836-B1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2024-09-18 EP disclosed
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2024-06-18 US disclosed
EP-3377483-B9 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-08-03 EP disclosed
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2022-06-09 US disclosed
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2022-02-08 US disclosed
EP-3928836-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2021-12-29 EP disclosed
CN-108349949-B N-substituted indole derivatives as PGE2 receptor modulators 爱杜西亚药品有限公司 2020-11-17 CN disclosed
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2020-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289507-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 KEAP1 2953/4885NFE2L2 757/4885AXL 2323/4885
US-20220175775-A1 N-SUBSTITUTED INDOLE DERIVATIVES AS PGE2 RECEPTOR MODULATORS PTGER1, PTGER4, PTGER2 KEAP1 2953/4885NFE2L2 757/4885AXL 2323/4885
US-12011444-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 KEAP1 2953/4885NFE2L2 757/4885AXL 2323/4885
US-11241431-B2 N-substituted indole derivatives as PGE2 receptor modulators PTGER1, PTGER4, PTGER2 KEAP1 2953/4885NFE2L2 757/4885AXL 2323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.